Zymeworks 5/8/2025 Earnings Report

Zymeworks EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.45
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Zymeworks Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $20.65 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Zymeworks Announcement Details

• Date: 5/8/2025
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Zymeworks (NYSE:ZYME), a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.